Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 455

1.

Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study.

Boland F, Galvin R, Reulbach U, Motterlini N, Kelly D, Bennett K, Fahey T.

BMC Pediatr. 2015 Sep 10;15:118. doi: 10.1186/s12887-015-0435-3.

2.

Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.

Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, Chiarotti F, Curatolo P.

CNS Drugs. 2015;29(10):865-77. doi: 10.1007/s40263-015-0266-7.

PMID:
26293742
3.

From the Editor-in-Chief's Desk.

Koplewicz HS.

J Child Adolesc Psychopharmacol. 2015 Aug;25(6):457. doi: 10.1089/cap.2015.29012.hsk. No abstract available.

PMID:
26262901
4.

Bipolar disorder and ADHD: comorbidity and diagnostic distinctions.

Marangoni C, De Chiara L, Faedda GL.

Curr Psychiatry Rep. 2015 Aug;17(8):604. doi: 10.1007/s11920-015-0604-y. Review.

PMID:
26084666
5.

Acute Dystonia After Stimulant Discontinuation in 2 ADHD Children Receiving Aripiprazole.

Párraga HC, Sherman BC.

J Clin Psychopharmacol. 2015 Aug;35(4):480-1. doi: 10.1097/JCP.0000000000000342. No abstract available.

PMID:
26035051
7.

[Hyperkinetic disorders in childhood and adolescence- an analysis of KinderAGATE 2009-2012].

Stegmann B, Rexroth CA, Wenzel-Seifert K, Haen E.

Z Kinder Jugendpsychiatr Psychother. 2015 Mar;43(2):101-14. German.

PMID:
25951625
8.

Grey matter volumes in treatment naïve vs. chronically treated children with attention deficit/hyperactivity disorder: a combined approach.

Villemonteix T, De Brito SA, Kavec M, Balériaux D, Metens T, Slama H, Baijot S, Mary A, Peigneux P, Massat I.

Eur Neuropsychopharmacol. 2015 Aug;25(8):1118-27. doi: 10.1016/j.euroneuro.2015.04.015. Epub 2015 Apr 18.

PMID:
25934396
9.

The Relationship between Acute Dyskinesia with a Single Dose of Methylphenidate and Recent Risperidone Discontinuation in a Child with Attention-Deficit/Hyperactivity Disorder.

Ince E, Algedik P, Demirdogen ES, Emul M, Demir T.

J Child Adolesc Psychopharmacol. 2015 May;25(4):378-9. doi: 10.1089/cap.2014.0148. Epub 2015 Apr 28. No abstract available.

PMID:
25920038
10.

Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.

Rundberg-Rivera EV, Townsend LD, Schneider J, Farmer CA, Molina BB, Findling RL, Gadow KD, Bukstein OG, Arnold LE, Kolko DJ, Buchan-Page KA, McNamara NK, Michel C, Austin A, Kipp H, Rice RR, Aman MG.

J Child Adolesc Psychopharmacol. 2015 Apr;25(3):225-33. doi: 10.1089/cap.2014.0097.

11.

Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.

Farmer CA, Brown NV, Gadow KD, Arnold LE, Kolko DG, Findling RL, Molina BS, Buchan-Page KA, Rice RR Jr, Bangalore SS, Bukstein O, Rundberg-Rivera EV, McNamara N, Aman MG.

J Child Adolesc Psychopharmacol. 2015 Apr;25(3):213-24. doi: 10.1089/cap.2014.0109.

12.

Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.

Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BS, Brown NV, Li X, Rundberg-Rivera EV, Bangalore S, Buchan-Page K, Hurt EA, Rice R, McNamara NK, Aman MG.

J Child Adolesc Psychopharmacol. 2015 Apr;25(3):203-12. doi: 10.1089/cap.2014.0104.

13.

Concurrent use of stimulants and second-generation antipsychotics among children with ADHD enrolled in Medicaid.

Kamble P, Chen H, Johnson ML, Bhatara V, Aparasu RR.

Psychiatr Serv. 2015 Apr 1;66(4):404-10. doi: 10.1176/appi.ps.201300391. Epub 2014 Dec 15.

PMID:
25828983
14.
15.

Medications used in the treatment of disruptive behavior in children with FASD--a guide.

Ozsarfati J, Koren G.

J Popul Ther Clin Pharmacol. 2015;22(1):e59-67. Epub 2015 Feb 12. Review.

16.

Does serotonin deficit mediate susceptibility to ADHD?

Banerjee E, Nandagopal K.

Neurochem Int. 2015 Mar;82:52-68. doi: 10.1016/j.neuint.2015.02.001. Epub 2015 Feb 12. Review.

PMID:
25684070
17.

Association between SNAP-25 gene polymorphisms and cognition in autism: functional consequences and potential therapeutic strategies.

Braida D, Guerini FR, Ponzoni L, Corradini I, De Astis S, Pattini L, Bolognesi E, Benfante R, Fornasari D, Chiappedi M, Ghezzo A, Clerici M, Matteoli M, Sala M.

Transl Psychiatry. 2015 Jan 27;5:e500. doi: 10.1038/tp.2014.136.

18.
19.

[The results of the pharmacological treatment of attention deficit hyperactivity disorder: evaluation with neuropsychological methods].

Zavadenko NN, Suvorinova NIu.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(9):19-24. Russian.

PMID:
25403296
20.

Combined stimulant and antipsychotic treatment in adolescents with attention-deficit/hyperactivity disorder: a cross-sectional observational structural MRI study.

Schweren LJ, Hartman CA, Zwiers MP, Heslenfeld DJ, van der Meer D, Franke B, Oosterlaan J, Buitelaar JK, Hoekstra PJ.

Eur Child Adolesc Psychiatry. 2015 Aug;24(8):959-68. doi: 10.1007/s00787-014-0645-5. Epub 2014 Nov 14.

PMID:
25395383
Items per page

Supplemental Content

Loading ...
Write to the Help Desk